6 To 7 Amino Acid Residues In Defined Sequence Patents (Class 530/329)
-
Patent number: 9012603Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: GrantFiled: December 18, 2009Date of Patent: April 21, 2015Assignee: Biogen Idec Hemophilia Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
-
Publication number: 20150104458Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.Type: ApplicationFiled: August 26, 2014Publication date: April 16, 2015Applicant: Biomay AGInventors: Rudolf VALENTA, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
-
Publication number: 20150105335Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.Type: ApplicationFiled: October 3, 2014Publication date: April 16, 2015Inventor: Richard Franklin
-
Publication number: 20150105316Abstract: This application describes compounds acting as, for example, ?-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases.Type: ApplicationFiled: December 22, 2014Publication date: April 16, 2015Inventors: Dennis Yamashita, Xiao-Tao Chen
-
Publication number: 20150104472Abstract: Isolated C1q peptides, fusion proteins and compositions comprising such and fusion proteins comprising are provided. Isolated fusion proteins comprising X4WX5YX6 as defined herein and compositions comprising such are also provided. Methods of treating autoimmune disorders are provided.Type: ApplicationFiled: July 15, 2014Publication date: April 16, 2015Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventor: Betty A. Diamond
-
Publication number: 20150105327Abstract: This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity.Type: ApplicationFiled: October 14, 2014Publication date: April 16, 2015Inventors: Woojin An, Nouri Neamati, Kyunghwan Kim
-
Publication number: 20150104473Abstract: The invention is directed to a compound according to the formula [1] wherein R1 and R2 are branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or 0 and R is —OH or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof. The invention is also directed to process for preparing said compound and the use of said compound as an adjuvant. The invention is also directed to a composition comprising said compound and the use of said composition, for example as a vaccine composition.Type: ApplicationFiled: October 4, 2012Publication date: April 16, 2015Inventors: Ferdinand Antonius Ossendorp, Cornelis Johannes Maria Melief, Selina Khan, Dmitri Viktorovistj Filippov, Gijsbert Arie Van Der Marel
-
Publication number: 20150104454Abstract: Embodiments of the invention are directed to a composition comprising a recombinant protein in soluble form wherein said recombinant protein comprises a portion of the Clostridium difficile toxin B sequence that comprises an epitope for anti-toxin B antibody. Other embodiments of the invention are directed to the generation of antibodies using peptide fragments of C. difficile toxin B.Type: ApplicationFiled: September 13, 2012Publication date: April 16, 2015Applicant: Board of Regents of the University of OklahomaInventors: Jimmy D. Ballard, Jordi M. Melton, Latisha Heinlen, Elaine E. Hamm
-
Patent number: 9006391Abstract: The present invention relates to a method for preparing cyclopeptides by means of protection with a substituted boronic acid. The present invention also discloses novel boronate esters of cyclopeptides of general formula (8).Type: GrantFiled: May 6, 2010Date of Patent: April 14, 2015Assignee: DSM Sinochem Pharmaceuticals Netherlands B.V.Inventors: Robertus Mattheus De Pater, Dhiredj Chandre Jagesar, Thomas Van Der Does
-
Publication number: 20150098990Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.Type: ApplicationFiled: October 8, 2014Publication date: April 9, 2015Inventors: Lawrence Chan, Hideto Kojima, Tomoya Terashima
-
Publication number: 20150098989Abstract: Compounds of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Yp—Zq—R2, their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.Type: ApplicationFiled: April 12, 2013Publication date: April 9, 2015Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
-
Patent number: 8999937Abstract: Polypeptide compositions that mimic the activity of glucocorticoid induced leucine zipper (GILZ) on the immune system are described. Also described is a method of treating multiple sclerosis using compositions comprising GILZ or lower molecular weight polypeptides with structural relationships to GILZ.Type: GrantFiled: February 28, 2012Date of Patent: April 7, 2015Assignee: Indiana University Research and Technology CorporationInventor: Mythily Srinivasan
-
Patent number: 8999919Abstract: The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface.Type: GrantFiled: November 9, 2011Date of Patent: April 7, 2015Assignee: Trustees of Dartmouth CollegeInventors: Dean R. Madden, Patrick R. Cushing, Prisca Boisguearin, Rudolph Volkmer, Lars Vouilleme
-
Patent number: 8999939Abstract: A hair treatment agent having advantageous properties is provided. The hair treatment agent contains, based on weight of the agent, 0.00001 to ?0.05% by weight of at least one oligopeptide having at least one amino acid sequence Glu-Glu-Glu (formula (A)), wherein the amino group may be present in a free or protonated manner, and the carboxy groups may be present in a free or deprotonated manner.Type: GrantFiled: January 8, 2013Date of Patent: April 7, 2015Assignee: Henkel AG & Co. KGaAInventors: Erik Schulze Zur Wiesche, Petra Westphal, Elisabeth Poppe
-
Patent number: 9000125Abstract: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.Type: GrantFiled: May 11, 2012Date of Patent: April 7, 2015Inventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische
-
Patent number: 8999932Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.Type: GrantFiled: July 29, 2010Date of Patent: April 7, 2015Assignee: KAI Pharmaceuticals, Inc.Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
-
Publication number: 20150093802Abstract: The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene.Type: ApplicationFiled: September 30, 2014Publication date: April 2, 2015Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITALInventors: Paul MCCRAY, Morgan MAEDER, Jae Keith JOUNG
-
Publication number: 20150093400Abstract: The present invention provides novel short peptides that are highly effective in inducing involution in a mammary gland of a lactating mammal and cessation of milk production by the gland. The invention further provides pharmaceutical composition comprising the peptides and methods of use thereof including for treating microbial infection in a mammary gland.Type: ApplicationFiled: March 8, 2013Publication date: April 2, 2015Inventors: Jose Mario Iscovich, Javier Iscovich
-
Patent number: 8993720Abstract: The disclosure provides methods of treating X-linked hypophosphatemia, related bone demineralization and renal phosphate wasting disorders in a mammalian subject. The methods comprise administering to the subject an effective amount of a polyarginine peptide.Type: GrantFiled: October 13, 2011Date of Patent: March 31, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Marc K. Drezner, Baozhi Yuan
-
Patent number: 8993721Abstract: Described herein is an isolated polypeptide which is capable of specifically targeting apoptotic cells undergoing apoptosis and consists of the sequence (I): Cys-X1-Val-Ala-Pro-X2 (I), wherein X1 is an amino acid with polar uncharged side chain and X2 is an amino acid with positive charged side chain. The isolated polypeptide of the present invention may be useful for detecting apoptotic cells, as well as detecting and imaging apoptotic cells in tumor tissue, apoptotic myocardial cells in myocardial infarction tissue, apoptotic nerve cells in stroke tissue, and arteriosclerosis site; the polypeptide is useful for targeted drug delivery thereto.Type: GrantFiled: May 9, 2012Date of Patent: March 31, 2015Inventors: Byung Heon Lee, In San Kim
-
Publication number: 20150087581Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.Type: ApplicationFiled: December 8, 2014Publication date: March 26, 2015Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Suresh Kumar Vadlamani, Koteswara Rao Vemula, Leena Khare Satyam, Krishnaprasad Subbarao, K. Rajeev Shrimali, Sreenivas Kandepu
-
Publication number: 20150086557Abstract: Provided is a novel ligand for integrin ?9?1 consisting of a peptide having the following amino acid sequence: (A) EDDMMEVPY (SEQ ID NO: 1) or (B) an amino acid sequence the same as the amino acid sequence represented by SEQ ID NO: 1 except for having deletion, substitution or addition of 1 to 3 amino acids. The novel ligand for integrin ?9?1 has a higher binding affinity than those of tenascin-C and osteodontin, which are known ligands for integrin ?9?1.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Inventors: Kiyotoshi Sekiguchi, Ryoko Sato, Sachiko Ezoe
-
Patent number: 8987377Abstract: The present invention provides poly(amide) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.Type: GrantFiled: November 16, 2011Date of Patent: March 24, 2015Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Stephanie E. Barrett, Marina Busuek, Steven L. Colletti, Robert M. Garbaccio, Erin N. Guidry, Robert A. Kowtoniuk, Jing Liao, Craig A. Parish, Rubina G. Parmar, Tao Pei, Kevin M. Schlosser, David M. Tellers, Sandra C. Tobias, Quang T. Truong, Jacob H. Waldman, Weimin Wang, J. Michael Williams
-
Patent number: 8987213Abstract: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof.Type: GrantFiled: November 27, 2013Date of Patent: March 24, 2015Assignee: Sanford-Burnham Medical Research InstituteInventors: Lianglin Zhang, Jason A Hoffman, Erkki Ruoslahti
-
Publication number: 20150080550Abstract: The present invention relates to a process for the production of bivalirudin, a 20-mer peptide of formula H-D-Phe1-Pro-Arg-Pro-Gly5-Gly-Gly-Gly-Asn-Gly10-Asp-Phe-Glu-Glu-Ile15-Pro-Glu-Glu-Tyr-Leu20-OH ??(I) via a convergent five-fragment synthesis, and to several peptide intermediates thereof.Type: ApplicationFiled: November 25, 2014Publication date: March 19, 2015Inventors: Geoffroy Sommen, Luciano Forni
-
Publication number: 20150079038Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.Type: ApplicationFiled: September 12, 2014Publication date: March 19, 2015Inventors: Benjamin E. Deverman, Paul H. Patterson
-
Patent number: 8980824Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.Type: GrantFiled: February 11, 2014Date of Patent: March 17, 2015Assignee: Bristol-Myers Squibb CompanyInventors: Qiang Cong, Heng Cheng, Sanjeev Gangwar
-
Publication number: 20150071974Abstract: Compounds of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 (I) their stereoisomers, mixtures thereof, their cosmetically or pharmaceutically acceptable salts and/or its functionally equivalent variants, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.Type: ApplicationFiled: April 12, 2013Publication date: March 12, 2015Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José Maria García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
-
Publication number: 20150073123Abstract: Synthetic peptides which have non-narcotic type of analgesic action which may be used in medicine and pharmacology as anesthetic anodynes according to the general formula 1 [SEQ ID NO:1] H-XDL-XDL1-XDL2-L-Lys-L-Leu-XDL3-L-Thr-R2.Type: ApplicationFiled: December 7, 2012Publication date: March 12, 2015Inventors: Gennady Petrovich VLASOV, Oleg Arkadyevich KOTIN, Arkadiy Mihajlovich KOTIN
-
Publication number: 20150072895Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: November 17, 2014Publication date: March 12, 2015Inventors: David B. KRIZMAN, Wei-Li LIAO, Sheeno THYPARAMBIL, Todd HEMBROUGH
-
Publication number: 20150071952Abstract: The invention provides peptides capable of binding with influenza hemagglutinin (HA) protein blocking pH-induced shape change or aggregation of the influenza hemagglutinin (HA) protein. The invention also provides a druggable site in influenza Hemagglutinin protein, said druggable site comprises peptide sequences comprising conserved residues.Type: ApplicationFiled: February 14, 2013Publication date: March 12, 2015Inventors: Ashish Fnu, Kalpana Pandey, Yogendra Rathore
-
Publication number: 20150065385Abstract: The invention provides an isolated peptide comprising a crotonylation site, a Kcr-specific affinity reagent that specifically binds to the peptide, and a method for detecting protein crotonylation in a sample using the reagent.Type: ApplicationFiled: November 3, 2014Publication date: March 5, 2015Applicant: PTM BIOLABS, INC.Inventors: YINGMING ZHAO, JEONG SOO YANG, HAO LUO, ZHONGYI CHENG
-
Publication number: 20150065424Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.Type: ApplicationFiled: November 17, 2014Publication date: March 5, 2015Applicant: VECTUS BIOSYSTEMS LIMITEDInventor: Karen Annette Duggan
-
Publication number: 20150064726Abstract: A method of bioassay for the quantification of peptide fragments relevant to neurodegenerative conditions comprising a neo-epitope formed by cleavage of a Tau protein by a secretase such as ADAM10 comprises contacting a blood derived sample with an antibody specific for the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. Neo-epitope containing peptide levels are found to be inversely correlated to cognitive function.Type: ApplicationFiled: July 4, 2012Publication date: March 5, 2015Applicant: Nordic Biosciences A/SInventors: Natasha Barascuk Michaelsen, Morten Karsdal, Kim Henriksen
-
Patent number: 8969252Abstract: The present invention includes methods for producing magnetic nanocrystals by using a biological molecule that has been modified to possess an amino acid oligomer that is capable of specific binding to a magnetic material.Type: GrantFiled: April 7, 2011Date of Patent: March 3, 2015Assignee: Board of Regents, University of Texas SystemInventors: Angela M. Belcher, Brian D. Reiss, Chuanbin Mao, Daniel J. Solis
-
Publication number: 20150057230Abstract: The present invention relates to a biotin-conjugated hexapeptide-2 derivative or a pharmaceutically acceptable salt thereof and use thereof. More particularly, the present invention relates to a biotin-conjugated hexapeptide-2 derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, a composition including the same as an active ingredient, and a method for improving wrinkles and inhibiting skin aging using the same.Type: ApplicationFiled: March 27, 2013Publication date: February 26, 2015Inventors: Kee-Don Park, Chae-Jin Lim, Seok-Jeong Yoon, Seon-Deok Kwon
-
Publication number: 20150057236Abstract: Sirt5, a mitochondrial Sirtuin, has been identified herein as an efficient demalonylase and desuccinylase. Disclosed herein are assays to identify Sirt5 modulators based on this robust enzymatic activity. Sirt5-specific modulators can be used study the biological function of Sirt5 and to target Sirt5 activities in treating human diseases.Type: ApplicationFiled: July 7, 2011Publication date: February 26, 2015Applicant: CORNELL UNIVERSITYInventor: Hening Lin
-
Publication number: 20150056209Abstract: Provided herein are peptide mimotopes that are useful for generating antibodies and in the preparation of vaccines and diagnostics for treating and diagnosing coronary artery disease.Type: ApplicationFiled: April 18, 2013Publication date: February 26, 2015Inventors: Joseph L. Witztum, Sotirios Tsimikas, Christoph Binder, Shahzada Amir
-
Publication number: 20150057217Abstract: The present invention relates to amphiphilic peptides having antibacterial and/or antitumor activity, and to therapeutic and non-therapeutic compositions comprising these peptides. The peptides are of structural formula I or II shown below wherein A1, v, A2, w, A3, x, y, A4, z, R1, R2 and R3 are as defined in the application; or a salt thereof. The invention further relates to use of the peptides as antibacterial agents, or antitumor agents, including the medical use of the peptide in treating infection and/or cancer, as well as their use as preservatives and antibacterial agents in other products, including personal care products such as skin topical treatments, cleansers, mouth washes, toothpastes, shampoo, body lotions and creams etc.Type: ApplicationFiled: March 11, 2014Publication date: February 26, 2015Inventors: Jian R. LU, Xiubo ZHAO, Fang PAN, Mohammed YASEEN
-
Patent number: 8962565Abstract: Peptide compounds of general formula (I) R1-(AA)n-X1—X2—X3-Asp-Leu-Lys-Lys-X4—X5-(AA)p-R2, cosmetic or pharmaceutical compositions comprising at least one peptide compound of general formula (I) in a physiologically acceptable medium, and methods for cosmetic treatment of skin are disclosed. The peptide compounds of general formula (I) were demonstrated to be agents making it possible to influence the pigmentation of the skin and skin appendages, by ensuring optimal transfer of the melanosomes to the keratinocytes, so as to make the skin tone uniform owing to an effect on the SCF/c-Kit signaling pathway. The compounds, compositions, and methods treat or attenuate age-related pigmentation defects and the effects of photoaging on the skin.Type: GrantFiled: January 30, 2012Date of Patent: February 24, 2015Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20150051093Abstract: The invention provides an isolated peptide comprising a lysine 3-hydroxybutyrylation site, a lysine 3-hydroxybutyrylation specific affinity reagent that specifically binds to the peptide, and a method for detecting protein lysine 3-hydroxybutyrylation in a sample using the reagent.Type: ApplicationFiled: August 18, 2014Publication date: February 19, 2015Applicant: PTM Biolabs, Inc.Inventors: Yingming Zhao, Zhongyu Xie
-
Publication number: 20150051151Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.Type: ApplicationFiled: March 14, 2013Publication date: February 19, 2015Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Michal Eisenbach-Schwartz, Matityahu Fridkin, Michal Cardon-Yaakov
-
Patent number: 8957016Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.Type: GrantFiled: May 31, 2012Date of Patent: February 17, 2015Inventors: Samuel R. Denmeade, John T. Isaacs
-
Patent number: 8957030Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: GrantFiled: February 27, 2013Date of Patent: February 17, 2015Assignees: Cornell Research Foundation, Inc., Institute de Recherches Cliniques de MontrealInventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
-
Patent number: 8957022Abstract: The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing. The present invention also features pharmaceutical compositions comprising the multimeric Tie 2 agonists, including those suitable for topical or systemic administration. Methods of using the multimeric Tie 2 agonists of the invention for stimulating angiogenesis and for promoting healing of wounds, such as diabetic ulcers or skin grafts, are also provided.Type: GrantFiled: October 26, 2007Date of Patent: February 17, 2015Assignee: Sunnybrook Health Sciences CentreInventors: Paul Van Slyke, Daniel Dumont
-
Patent number: 8957185Abstract: Peptides from the MUC1 cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.Type: GrantFiled: February 24, 2012Date of Patent: February 17, 2015Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLCInventors: Donald W. Kufe, Surender Kharbanda
-
Oligopeptide for treating liver fibrosis and/or treating hepatitis B and/or improving liver function
Patent number: 8957019Abstract: Disclosed is an oligopeptide for treating liver fibrosis and/or hepatitis B and/or improving liver function. The oligopeptide is obtained by reflux extraction via water, ethanol precipitation and isolation through a cation exchange resin column and a gelatinous resin column from a turtle shell. Pharmaceutically conventional excipients can be added to the oligopeptide prepared according to the present invention to prepare various dosage forms. The oligopeptide has good efficacy in treating liver fibrosis and improving liver function.Type: GrantFiled: November 1, 2011Date of Patent: February 17, 2015Inventors: Haimin Lei, Qiang Li -
Publication number: 20150045288Abstract: The present invention relates to anti-contaminant composition comprising a cell-free fermentation product of one or more Bacillus subtilis strains (e.g., selected from the group consisting of: 22C-P1, 15A-P4, 3A-P4, LSSA01, ABP278, BS 2084 and BS 18); wherein said fermentation product comprises one or more compounds selected from the group consisting of: a lipopeptide, a polyketide, a bacillibactin, a bacilysin, an anticapsin, a plantazolicin, a LCI, a homologue of a plantazolicin and a homologue of a LCI. In addition, the present invention further relates to methods of preparing the compositions, methods of using the composition, products comprising the composition and uses thereof.Type: ApplicationFiled: February 20, 2013Publication date: February 12, 2015Inventors: Tina Mygind, George H. Weber, Connie Benfeldt, Ashley Ann Hibberd, Rebecca Joy Landrum, Panagiotis Chanos, Gregory R. Siragusa, Matthew James Hundt
-
Publication number: 20150045283Abstract: The present invention provides novel PAR lderived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met1-Arg46 deleted human PAR 1 sequence. These cytoprotective oligopeptides or polypeptides are capable of activating PAR 1 and promoting PAR 1 cytoprotective signaling activities. The invention also provides engineered cells or transgenic non-human animals which harbor in their genome an altered PAR 1 gene that is resistant to cleavage at Arg41 and/or Arg46 residues. Additionally provided in the invention are methods of screening candidate compounds to identity additional cytoprotective compounds or cytoprotective proteases. The invention further provides therapeutic use or methods of employing a PAR 1 derived cytoprotective oligopeptide or polypeptide to treat conditions associated with tissue injuries or undesired apoptosis.Type: ApplicationFiled: November 7, 2012Publication date: February 12, 2015Inventors: Laurent O. Mosnier, John H. Griffin
-
Patent number: 8952127Abstract: The present invention provides for a bio-mimetic polymer capable of catalyzing CO2 into a carbonate.Type: GrantFiled: June 3, 2011Date of Patent: February 10, 2015Assignee: The Regents of the University of CaliforniaInventors: Chun-Long Chen, Ronald N. Zuckermann, James J. De Yoreo